Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

erapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity or hearing loss, toxicities commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in patients with mCRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of hormone refractory prostate cancer (HRPC). Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone- refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by regulatory authority for use in humans. Fo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
(Date:5/23/2013)... 2013  Texas, premier physician associations today announced the ... tools they need to provide demonstrably better and more ... marketplace. "I am confident the Physician Services ... Stephen L. Brotherton , MD, president ... doctors are determined to make health care ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
(Date:5/25/2013)... York (PRWEB) May 25, 2013 ... litigation underway in U.S. District Court, Western District of ... According to a Case Management Order issued on ... the filing of contested motions in the Actos bladder ... motions. (In re: Actos Product Liability Litigation, MDL No. ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market (2012 – ... Materials, Packaging, & Geography: Trends & Forecasts” defines ... analysis and forecasting of the global revenue for ... restraining factors for the global food encapsulation markets ... market is segmented and revenue are forecasted on ...
(Date:5/25/2013)... 25, 2013 Providing patients with their best ... team of weight management professionals. But, aside from educating patients ... Diet Doc’s hCG diets also provide patients, who ... childhood like bullying, more control over their lives by achieving ... with the underlying factors of weight gain derived from earlier ...
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... patients who allegedly suffered serious, life-threatening episodes of internal bleeding ... federal litigation underway in U.S. District Court, Southern District of ... on the Court’s website, 818 Pradaxa side effect claims had ... 24, 2013. That’s up from 705 claims reported by ...
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 ... organization dedicated to brain cancer research and advocacy, comments ... for Extraterrestrial Physics, that shows incorporating cold atmospheric plasma ... glioblastoma cells. , According to a Science ... for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... to new therapeutic targets , , TUESDAY, June 24 (HealthDay ... factor in the development of B-cell lymphomas, one of ... with mice, researchers at the National Jewish Medical and ... the surface of B-cells can cooperate with the MYC ...
... 24 Behavioral Risk Management is an,important best ... message from,a survey conducted by the Disability Management ... in Behavioral Risk,Management., Additionally, survey results show ... emerging focus area to one that is showing ...
... programs due Aug. 7, WASHINGTON, June ... group for creation of accreditation standards and ... requests for quality standards,and measures for both ... 50 advisory committee members include employers, health ...
... leading brand of vitamin, mineral and dietary supplements hits, record milestone; ... ... health, ADA, Mich., June 24 NUTRILITE, the world,s leading,brand ... sales over the last 12 months as Amway/Quixtar,s message of,optimal health ...
... LONDON, June 24 NHS Choices ( http://www.nhs.uk ... a Live well guide on women,s,health aged 18-39 ... maintaining a,healthy lifestyle., Based on NHS accredited ... provides users with information about,walking to get healthy, ...
... Region of the American Red Cross is facing alarmingly ... of local hospitals. The,morning began with five of the ... zero O-, the universal blood type. In order,to meet ... Region should,maintain a minimum three-day supply of all eight ...
Cached Medicine News:Health News:Research Uncovers Clues to Lymphoma 2Health News:Behavioral Risk in the Workplace: Behavioral Risk Management Continues to be an Important Best Practice Area for Employers 2Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 2Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 3Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 4Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 5Health News:NUTRILITE(TM) Passes $3 Billion Mark in Annual Sales 2Health News:NUTRILITE(TM) Passes $3 Billion Mark in Annual Sales 3
... Agility is positioned to support ... to reduce medication and other ... workflow for pharmacy support staff ... blood products, lab specimens and ...
... Context-sensitive medicine is the ability of medical ... pre-determined ways based on what is happening ... associations a Radianse indoor positioning solution (IPS) ... it requires identity, location and time to ...
... VerdaSee Intelli-Storeroom™ was developed to create physically ... entrances and exits are converted to RFID ... RFID readers and antennas by VerdaSee's Field ... affixed to assets that are to be ...
... ability to track the movement of ... assets can be done. VerdaSee's "intellishelvess" ... Continuous cycle counting is possible with ... (RFID) technology makes this possible. VerdaSee ...
Medicine Products: